Disclose an Invention

Connect with UIRF

Join our inventor office hour the first Tuesday of every month from 4-5pm.

View Available Technologies

Attend a Class

Learn about intellectual property, licensing, and commercialization at one of our virtual classes.

Unsure where to start?

Our staff are here to help guide UI innovators who want to commercialize new innovations.


Latest Innovations

A Novel Method to Make Wettability Pattern for Metal Surfaces

Multilevel Dynamic Regenerative Braking (DRB) System

Phytoestrogen Plus Gut Bacteria as a Treatment for MS

Method of Treating Periodontitis

News feed

Cardio Diagnostics Holdings, Inc. to List on Nasdaq Following Successful Business Combination with Mana Capital Acquisition Corp.

Cardio Diagnostics Holdings, Inc., a pioneering precision cardiovascular medicine company founded by UI faculty Dr. Robert Philibert and UI graduate Dr. Meesha Dogan, today announced the completion of its business combination with Mana Capital Acquisition Corp., a publicly traded special purpose acquisition company.

Lilly to Acquire Akouos for Up to $610M, Expanding Gene Therapy Focus

Eli Lilly has agreed to acquire Akouos for up to $610 million, in a deal intended to expand the buyer’s presence in gene therapy with a focus on treating inner ear disorders. Akouos, which has licensed key technology from the University of Iowa, develops targeted adeno-associated viral (AAV) vector-based gene therapies for conditions that include sensorineural hearing loss, integrating expertise in otology and inner ear drug delivery, as well as gene therapy.

Explore the tech transfer process through live virtual courses with commercialization experts

The University of Iowa Research Foundation (UIRF) will host a series of online courses about how to move technology from the university to the marketplace for all University of Iowa faculty, staff, postdocs, and graduate students.

Villafana-led Medtech Firm Medical 21 Secures $20M in Financing

Medical device company Medical 21, founded on technology developed at the UI by Prof. Suresh Raghavan, announced that it has landed a $20 million commitment from an individual investor.

Viewpoint Molecular Targeting Announces Transformational Merger

Viewpoint Molecular Targeting, UI start-up company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced that it has entered into a definitive agreement to merge with Isoray, Inc (NYSE AMERICAN:ISR), a medical technology company and innovator in seed brachytherapy.


New Licenses and options granted to UI technologies



New patent applications



New invention disclosures